Literature DB >> 22451514

Nasopharyngeal colonization elicits antibody responses to staphylococcal and pneumococcal proteins that are not associated with a reduced risk of subsequent carriage.

Sabine M P J Prevaes1, Willem J B van Wamel, Corné P de Vogel, Reinier H Veenhoven, Elske J M van Gils, Alex van Belkum, Elisabeth A M Sanders, Debby Bogaert.   

Abstract

Knowledge of the immunological correlates of Staphylococcus aureus and Streptococcus pneumoniae colonization is required for the search for future protein vaccines. We evaluated natural antibody levels against pneumococcal and staphylococcal proteins in relation to previous bacterial colonization with both pathogens. In a randomized controlled trial, nasopharyngeal samples were obtained from children at 1.5, 6, 12, 18, and 24 months and cultured for S. aureus and S. pneumoniae. Approximately 50% of the children were PCV7 vaccinated. Serum IgG against 18 pneumococcal and 40 staphylococcal proteins was semiquantified by Luminex technology from 111 12 month olds and 158 24 month olds. Previous culture-proven S. aureus colonization was associated with higher IgG levels against 6/40 staphylococcal proteins (ClfB, ClfA, Efb, CHIPS, LukD, and LukF [P ≤ 0.001]) compared to noncarriers. Previous pneumococcal colonization was associated with increased IgG levels against 12/18 pneumococcal proteins compared to noncarriers (P ≤ 0.003). Increasing age was associated with higher levels of antibodies to most pneumococcal proteins and lower levels of antibodies to over half the staphylococcal proteins, reflecting natural colonization dynamics. Anti-S. pneumoniae and anti-S. aureus protein antibodies at the age of 12 months were not negatively correlated with subsequent colonization with the homologous species in the following year and did not differ between PCV7-vaccinated and nonvaccinated children. Colonization with S. aureus and S. pneumoniae induces serum IgG against many proteins, predominantly proteins with immune-modulating functions, irrespective of PCV7 vaccination. None of them appeared to be protective against new acquisition with both pathogens, possibly due to the polymorphic nature of those proteins in the circulating bacterial population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451514      PMCID: PMC3370583          DOI: 10.1128/IAI.00037-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.

Authors:  Clayton Harro; Robert Betts; Walter Orenstein; Eun-Jeong Kwak; Howard E Greenberg; Matthew T Onorato; Jon Hartzel; Joy Lipka; Mark J DiNubile; Nicholas Kartsonis
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

Review 2.  Colonization and infection of the human host by staphylococci: adhesion, survival and immune evasion.

Authors:  Timothy J Foster
Journal:  Vet Dermatol       Date:  2009-10       Impact factor: 1.589

Review 3.  Streptococcus pneumoniae: virulence factors and variation.

Authors:  A M Mitchell; T J Mitchell
Journal:  Clin Microbiol Infect       Date:  2010-02-02       Impact factor: 8.067

4.  Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA.

Authors:  Gili Regev-Yochay; William P Hanage; Krzysztof Trzcinski; Sheryl L Rifas-Shiman; Grace Lee; Andrew Bessolo; Susan S Huang; Stephen I Pelton; Alexander J McAdam; Jonathan A Finkelstein; Marc Lipsitch; Richard Malley
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

5.  Novel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice.

Authors:  Thorunn Asta Olafsdottir; Karen Lingnau; Eszter Nagy; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2011-10-24       Impact factor: 3.441

6.  Induction of antibodies by Staphylococcus aureus nasal colonization in young children.

Authors:  N J Verkaik; A Lebon; C P de Vogel; H Hooijkaas; H A Verbrugh; V W V Jaddoe; A Hofman; H A Moll; A van Belkum; W J B van Wamel
Journal:  Clin Microbiol Infect       Date:  2009-10-14       Impact factor: 8.067

7.  Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses.

Authors:  Gerwin D Rodenburg; Elske J M van Gils; Reinier H Veenhoven; Nienke Jones; Irina Tcherniaeva; Eelko Hak; Loek van Alphen; Guy A M Berbers; Elisabeth A M Sanders
Journal:  Vaccine       Date:  2009-11-18       Impact factor: 3.641

Review 8.  Versatility of choline metabolism and choline-binding proteins in Streptococcus pneumoniae and commensal streptococci.

Authors:  Regine Hakenbeck; Abderrahim Madhour; Dalia Denapaite; Reinhold Brückner
Journal:  FEMS Microbiol Rev       Date:  2009-05       Impact factor: 16.408

9.  Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits.

Authors:  Angelique G S C Jansen; Gerwin D Rodenburg; Sabine C de Greeff; Eelko Hak; Reinier H Veenhoven; Lodewijk Spanjaard; Leo M Schouls; Elisabeth A M Sanders; Arie van der Ende
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

10.  Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions.

Authors:  Alex J McCarthy; Jodi A Lindsay
Journal:  BMC Microbiol       Date:  2010-06-15       Impact factor: 3.605

View more
  23 in total

1.  Correlation of higher antibody levels to pneumococcal proteins with protection from pneumococcal acute otitis media but not protection from nasopharyngeal colonization in young children.

Authors:  Q Xu; J R Casey; A Almudevar; M E Pichichero
Journal:  Clin Microbiol Infect       Date:  2017-01-28       Impact factor: 8.067

Review 2.  Staphylococcus aureus and Streptococcus pneumoniae interaction and response to pneumococcal vaccination: Myth or reality?

Authors:  Aylana Reiss-Mandel; Gili Regev-Yochay
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

3.  Co-colonization by Haemophilus influenzae with Streptococcus pneumoniae enhances pneumococcal-specific antibody response in young children.

Authors:  Qingfu Xu; Michael E Pichichero
Journal:  Vaccine       Date:  2013-12-16       Impact factor: 3.641

4.  Comparative Exoproteomics and Host Inflammatory Response in Staphylococcus aureus Skin and Soft Tissue Infections, Bacteremia, and Subclinical Colonization.

Authors:  Yun Khoon Liew; Rukman Awang Hamat; Alex van Belkum; Pei Pei Chong; Vasanthakumari Neela
Journal:  Clin Vaccine Immunol       Date:  2015-03-25

5.  Modeling specific antibody responses to natural immunization to predict a correlate of protection against infection before commencing a clinical vaccine trial.

Authors:  Anthony Almudevar; Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 6.  Next generation protein based Streptococcus pneumoniae vaccines.

Authors:  Michael E Pichichero; M Nadeem Khan; Qingfu Xu
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

7.  Clinical characteristics of children with lower respiratory tract infections are dependent on the carriage of specific pathogens in the nasopharynx.

Authors:  T Tenenbaum; A Franz; N Neuhausen; R Willems; J Brade; S Schweitzer-Krantz; O Adams; H Schroten; B Henrich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-01       Impact factor: 3.267

8.  A protein A based Staphylococcus aureus vaccine with improved safety.

Authors:  Miaomiao Shi; Xinhai Chen; Yan Sun; Hwan Keun Kim; Olaf Schneewind; Dominique Missiakas
Journal:  Vaccine       Date:  2021-06-01       Impact factor: 4.169

9.  Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.

Authors:  Gerwin D Rodenburg; Elisabeth A M Sanders; Elske J M van Gils; Reinier H Veenhoven; Tomasz Zborowski; Germie P J M van den Dobbelsteen; Andries C Bloem; Guy A M Berbers; Debby Bogaert
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

10.  Increased IgG but normal IgA anti-pneumococcal protein antibodies in lung of HIV-infected adults.

Authors:  Andrea M Collins; Sherouk El Batrawy; Stephen B Gordon; Daniela M Ferreira
Journal:  Vaccine       Date:  2013-05-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.